Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Curative Biotechnology, Inc. develops biomedical therapies with a current focus on degenerative eye diseases. Company news centers on its metformin-based topical ophthalmic formulation, a program supported by a worldwide exclusive license from the National Eye Institute at the NIH and a Cooperative Research and Development Agreement with the NEI. Updates also cover research agreements, clinical-supply manufacturing for sterile ophthalmic drops, and translational work spanning age-related macular degeneration and veterinary retinal degeneration models.
Recurring corporate developments include capital-structure actions such as the completed reverse stock split, strategic and financial advisory engagements, board and clinical-development governance updates, and material agreements tied to the company’s ophthalmology platform.
Curative Biotechnology (OTC: CUBT) entered a Sponsored Research Agreement with PennVet on May 7, 2026 to fund a non-clinical canine study of GMP-grade metformin ophthalmic drops.
The study will use a PDE6-associated retinal degeneration canine model to assess safety, tolerability, ERG, imaging, histopathology, and potential neuroprotective biological activity.
Curative Biotechnology (OTC: CUBT) engaged Sterling Pharmaceutical Services to manufacture clinical supply of a metformin-based topical ophthalmic formulation, advancing toward a planned first-in-human Phase 1 study in dry Age-Related Macular Degeneration (AMD) and a clinical K9 PDE6 retinal degeneration study.
The work supports the Company’s CRADA with NIH and follows Curative’s 1-for-150 reverse stock split as it pursues an uplist to the OTCQB Venture Market.
Curative Biotechnology (CUBT, temporarily CUBTD) executed a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and DTC-eligible shares from ~266.8 million to ~1.78 million. The company's ticker will show as CUBTD for 20 trading days.
Curative plans manufacturing to begin mid-April 2026, received a U.S. manufacturer proposal for sterile metformin ophthalmic drops, intends a Phase 1 NIH CRADA human study for dry AMD, and will pursue an OTCQB uplisting after a manufacturing agreement.
Curative Biotechnology (OTC: CUBT) implemented a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and temporarily changing its ticker to CUBTD for 20 trading days.
The company received a U.S. manufacturing proposal to produce sterile metformin ophthalmic drops, plans manufacturing to begin mid-April 2026, intends a first-in-human Phase 1 study under an NIH CRADA for dry AMD, and aims to pursue an OTCQB uplist after executing a manufacturing and product development agreement.
Curative Biotechnology (OTC: CUBT) announced that the Canadian Intellectual Property Office issued a Notice of Allowance for Canadian Patent Application No. 3,151,011 titled “Druggable Target to Treat Retinal Degeneration.” Curative is the exclusive worldwide licensee under an agreement with the National Eye Institute, and the invention was developed by Dr. Kapil Bharti and team. The allowance includes 22 allowed claims covering topical ocular delivery approaches relevant to metformin-based formulations and is expected to formally issue in the coming months. The company also noted parallel development into select canine retinal indications such as PRA and PRCD.
Curative Biotechnology (OTC: CUBT) announced a strategic redirection focused on sublicensing and manufacturing partnerships, a revised reverse stock split, and withdrawal of a planned S-1 public offering.
Key actions: pursuing a sublicence/manufacturing agreement for its metformin-based eye drops; targeting simultaneous human Dry AMD and canine indications (CPRA with a single 24-dog accelerated trial; PRA with ~300-dog effectiveness trial); withdrawing the S-1; and approving a 150-to-1 reverse split (replacing 400-to-1) pending FINRA approval. The company also plans to apply to uplist to the OTCQB after the sublicense and reverse split.
Curative Biotechnology (OTC: CUBT), a development-stage biomedical company specializing in treatments for degenerative eye diseases, has announced the appointment of Golden Eagle Capital Advisors (GECA) as its exclusive agent and strategic advisor. GECA, a Dubai-based financial advisory group, will provide strategic guidance to support CUBT's business objectives.
Summary not available.
Summary not available.
Summary not available.